Dual antiplatelet therapy with clopidogrel and aspirin

American Journal of Health-System Pharmacy

Volumn 65, Issue 12, 2008, Pages 1134-1143

  Sullivan, Joshua ^a   Amarshi, Naseem ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Aspirin; Clopidogrel; Combined therapy; Coronary artery bypass; Hemorrhage; Platelet aggregation inhibitors; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; IRBESARTAN; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; PACLITAXEL; PLACEBO; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BRACHYTHERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; ST SEGMENT ELEVATION; STENT; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

EID: 45849134175     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060662     Document Type: Review

References (42)

1. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics - 2007 update: a report of the American Heart Association Statistics Committee and Stroke Subcommittee. Circulation. 2007; 115:e69-171. [Erratum, Circulation. 2007; 115:e172.]
2. Patrono C, Rodriguez LA, Landolfi R et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353:2373-83.
3. When to use aspirin with clopidogrel (Plavix). Pharmacist Lett. 2006; 22: 220509.
4. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk for Ischaemic Events (CAPRIE). Lancet. 1996; 348:1329-39.
5. Plavix (clopidogrel bisulfate) package insert. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals; 2007.
6. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA). N Engl J Med. 2006; 354:1706-17.
7. Gurbuz AT, Zia AA, Vuran AC et al. Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. Eur J Cardiothorac Surg. 2006; 29:190-5.
8. Halkos ME, Cooper WA, Petersen R et al. Early administration of clopidogrel is safe after off-pump coronary artery bypass surgery. Ann Thorac Surg. 2006; 81:815-9.
9. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502. [Errata, N Engl J Med. 2001; 345:1506,1716.]
10. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358:527-33.
11. Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288:2411-20. [Erratum, JAMA. 2003; 289:987.]
12. Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005; 294:1224-32.
13. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:1607-21.
14. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic for myocardial infarction with ST-segment elevation. Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction (CLARITY-TIMI 28 study). N Engl J Med. 2005; 352:1179-89.
15. Serebruany VL, Malinin AI, Jerome SD et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment of Congestive Heart Failure (PLUTO-CHF) trial. Amer Heart J. 2003; 146:713-20.
16. Markus HS, Droste DW, Kaps M et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005; 111:2233-40.
17. Charlson ME, Isom OW. Care after coronary-artery bypass surgery. N Engl J Med. 2003; 328:1456-63.
18. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364:331-7.
19. ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S, Pogue J et al. Clopidogrel plus aspirin versus oral anticoagulation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367:1903-12.
20. ClinicalTrials.gov. Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE). www.clinicaltrials.gov/ct2/show/ NCT00249873?term=ACTIVE+A&rank=1 (accessed 2008 Mar 19).
21. Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004; 110:2747-71.
22. American Diabetes Association. Standards of medical care in diabetes. VI. Prevention and management of diabetes complications. Diabetes Care. 2006; 29(suppl 1):S17-26.
23. Scottish Intercollegiate Guidelines Network. Management of diabetes. A national clinical guideline. www.sign.ac.uk/guidelines/fulltext55 (accessed 2006 Jul 10)
24. Antman EM, Hand M, Armstrong PW et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians. Circulation. 2008; 117:296-329. [Erratum, Circulation. 2008; 117:e162.]
25. National Institute for Clinical Excellence. Clopidogrel in the treatment of non-ST-segment-elevation. www.nice.org.uk/guidance (accessed 2006 Jul 10).
26. Bertrand ME, Simoons ML, Fox KA et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002; 23:1809-40.
27. Silber S, Albertsson P, Aviles FF et al. Guidelines for percutaneous coronary interventions. Eur Heart J. 2005; 26:804-47.
28. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2007; 116:803-77.
29. Institute for Clinical Systems Improvement (ICSI). Diagnosis and treatment of chest pain and acute coronary syndrome. www.icsi.org/ guidelines_and_more (accessed 2006 Jul 10).
30. Finnish Medical Society Duodecim. Myocardial infarction. www.guidelines.gov (accessed 2006 Jul 10).
31. King SB, Smith SC, Hirshfeld JW et al. 2007 focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2008; 117:261-95. [Erratum, Circulation. 2008; 117:e161.]
32. Popma JJ, Berger P, Ohman EM et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3, suppl):576S-99S.
33. Grines CL, Bonow RO, Casey DE et al. Prevention of premature discontinuation of dual antiplatelet therapy with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007; 115:813-8.
34. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48:193-202.
35. Kotani J, Awata M, Nanto S et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006; 47:2108-11.
36. Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006; 47:175-81.
37. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004; 109:701-5.
38. Harrington RA, Becker RC, Ezekowitz M et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3, suppl):513S-48S.
39. Institute for Clinical Systems Improvement. Stable coronary artery disease. www.icsi.org/guidelines_and_more (accessed 2006 Jul 10).
40. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49:1982-8.
41. Wang TH, Bhatt DL, Fox KA et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J. 2007; 28:2200-7.
42. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke. 2006; 37:577-617.